SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-20-117128
Filing Date
2020-04-23
Accepted
2020-04-23 16:00:36
Documents
2
Group Members
PONTIFAX (CAYMAN) IV, L.P.PONTIFAX (CHINA) IV, L.P.PONTIFAX (ISRAEL) IV, L.P.PONTIFAX LATE STAGE FUND, L.P.PONTIFAX LATE STAGE GP LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D d921303dsc13d.htm SC 13D 125700
2 EX-99.2 d921303dex992.htm EX-99.2 8506
  Complete submission text file 0001193125-20-117128.txt   135986
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91484 | Film No.: 20810991
SIC: 2834 Pharmaceutical Preparations

Mailing Address 14 SHENKAR STREET, BEIT OFEK HERZLIYA PITUACH L3 46140
Business Address 14 SHENKAR STREET, BEIT OFEK HERZLIYA PITUACH L3 46140 972-9-9725617
Pontifax Management 4 G.P. (2015) Ltd. (Filed by) CIK: 0001726334 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: SC 13D